Myriad Genetics financials
$4.23−0.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 | FY16 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M | $557.1M | $851.1M | $743.7M | $728.7M | $740.5M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | $493.0M | $378.9M | $650.1M | $566.5M | $557.5M | $583.2M |
| Gross margin | 69.9% | 69.9% | 68.6% | 70.2% | 71.4% | 68.0% | 76.4% | 76.2% | 76.5% | 78.8% |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M | -$289.7M | $7.6M | $121.9M | $44.0M | $153.4M |
| Net income | -$365.9M | -$127.3M | -$263.3M | -$112.0M | -$27.2M | -$223.6M | $4.6M | $133.3M | $17.4M | $117.2M |
| Net margin | −44.4% | −15.2% | −35.0% | −16.5% | −3.9% | −40.1% | 0.5% | 17.9% | 2.4% | 15.8% |
| Diluted EPS | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 | $0.06 | $1.85 | $0.25 | $1.60 |
| EBITDA | -$14.1M | -$5.5M | -$195.5M | -$71.0M | -$113.1M | -$191.3M | $81.7M | $115.1M | $91.5M | $180.2M |
| Operating cash flow | $1.8M | -$8.7M | -$110.9M | -$106.3M | $18.6M | — | $83.7M | $115.9M | $106.2M | $166.3M |
| Free cash flow | -$13.8M | -$27.7M | -$174.1M | -$151.6M | $600.0K | — | $75.1M | $107.5M | $100.1M | $161.3M |
| Diluted shares | 92.6M | 90.6M | 82.8M | 80.6M | 78.0M | 74.8M | 76.0M | 72.0M | 68.8M | 73.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $149.6M | $102.4M | $132.1M | $56.9M | $257.4M | $117.0M |
| Short-term investments | $0.00 | $0.00 | $8.8M | $58.0M | $81.4M | $33.7M |
| Total debt | $119.9M | $39.6M | $38.5M | $0.00 | $0.00 | $224.8M |
| Total assets | $706.6M | $1.03B | $1.15B | $1.20B | $1.32B | $1.42B |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M | $537.8M |
| Shareholders' equity | $368.0M | $701.1M | $783.2M | $885.8M | $967.8M | $881.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology